Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 17/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 16/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948267 | 0.81 | PRKCQ (0.43) | PRKCQPRKCDLCKFYNLYN | |
| SCHEMBL4948258 | 0.81 | PRKCQ (0.43) | PRKCQPRKCDLCKFYNLYN | |
| SCHEMBL4947940 | 0.80 | CSNK1A1 (0.36) | CYP2A6PRKCQPRKCDLYNCSNK1A1 | |
| SCHEMBL30727714 | 0.77 | CYP2A6 (0.35) | CYP2A6PRKCQPRKCDLYNSRC | |
| SCHEMBL3993667 | 0.77 | CSNK1A1 (0.34) | CYP2A6PRKCQPRKCDLYNSRC | |
| SCHEMBL3996010 | 0.77 | CYP2A6 (0.35) | CYP2A6PRKCQPRKCDLYNSRC | |
| SCHEMBL3992555 | 0.77 | CSNK1A1 (0.34) | CYP2A6PRKCQPRKCDSRCCSNK1A1 | |
| SCHEMBL4898827 | 0.77 | SRC (0.32) | SRCCSNK1A1CLK4 | |
| SCHEMBL4947800 | 0.77 | SLC22A12 (0.40) | — | |
| SCHEMBL4944952 | 0.75 | EGFR (0.45) | PRKCQPRKCDLCKLYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| WO-2007038519-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | CYP2A6 2462/4885PRKCQ 286/4885PRKCD 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.